Two high-profile downgrades stood out in today's analyst activity. TGT fell out of favour as analysts cut their rating. The consensus slipped from 4 buy recommendations to 3. The average target price dropped to $147.78. Short interest is modest at 3.6% of free float, suggesting bears are not piling in — yet.
IBM also took a hit with a fresh downgrade. One analyst shifted to sell, nudging the sell count to 14. The average target price slipped to $244.91.
On the brighter side, KEYS (Keysight Technologies) scored an upgrade. The average target price jumped to $415.08 from $388.33 — a $27 lift. Short interest is just 1.9% of free float. Analysts appear confident in the test and measurement equipment maker's outlook.
MRNA also got a boost. William Blair's Myles Minter upgraded Moderna to Buy from Hold. Short interest stands at 13.5% of free float. That's a meaningful short position. A fresh buy call on a heavily shorted name adds squeeze potential.
ADI and both saw target price increases, adding to a broadly constructive tone in financials and semiconductors despite the retail and tech downgrades.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
